#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Recognizing patients with monogenic AIDs is difficult because their clinical spectrum may range from very mild inflammatory episodes to severe chronic disease .
2-1	14-25	Recognizing	_	_	_	_
2-2	26-34	patients	person[2]	new[2]	ana	2-9[0_2]
2-3	35-39	with	person[2]	new[2]	_	_
2-4	40-49	monogenic	person[2]|abstract[3]	new[2]|new[3]	coref	9-6[0_3]
2-5	50-54	AIDs	person[2]|abstract[3]	new[2]|new[3]	_	_
2-6	55-57	is	_	_	_	_
2-7	58-67	difficult	_	_	_	_
2-8	68-75	because	_	_	_	_
2-9	76-81	their	person|abstract[5]	giv|new[5]	coref	4-19
2-10	82-90	clinical	abstract[5]	new[5]	_	_
2-11	91-99	spectrum	abstract[5]	new[5]	_	_
2-12	100-103	may	_	_	_	_
2-13	104-109	range	_	_	_	_
2-14	110-114	from	_	_	_	_
2-15	115-119	very	event[6]	new[6]	_	_
2-16	120-124	mild	event[6]	new[6]	_	_
2-17	125-137	inflammatory	event[6]	new[6]	_	_
2-18	138-146	episodes	event[6]	new[6]	_	_
2-19	147-149	to	_	_	_	_
2-20	150-156	severe	abstract[7]	new[7]	coref	3-4[0_7]
2-21	157-164	chronic	abstract[7]	new[7]	_	_
2-22	165-172	disease	abstract[7]	new[7]	_	_
2-23	173-174	.	_	_	_	_

#Text=Moreover , the disease features significantly overlap .
3-1	175-183	Moreover	_	_	_	_
3-2	184-185	,	_	_	_	_
3-3	186-189	the	_	_	_	_
3-4	190-197	disease	abstract	giv	coref	12-9[90_0]
3-5	198-206	features	_	_	_	_
3-6	207-220	significantly	_	_	_	_
3-7	221-228	overlap	_	_	_	_
3-8	229-230	.	_	_	_	_

#Text=Our targeted NGS approach resulted in genetic confirmation in a relatively small proportion ( 7 % ) of patients .
4-1	231-234	Our	person|abstract[11]	acc|new[11]	ana|coref	5-29|18-4[124_11]
4-2	235-243	targeted	abstract[11]	new[11]	_	_
4-3	244-247	NGS	abstract|abstract[11]	new|new[11]	coref	11-10
4-4	248-256	approach	abstract[11]	new[11]	_	_
4-5	257-265	resulted	abstract	new	none|none	4-5[0_179]|23-9
4-6	266-268	in	_	_	_	_
4-7	269-276	genetic	abstract[12]	new[12]	coref	17-15[112_12]
4-8	277-289	confirmation	abstract[12]	new[12]	_	_
4-9	290-292	in	_	_	_	_
4-10	293-294	a	abstract[13]	new[13]	appos	4-15[14_13]
4-11	295-305	relatively	abstract[13]	new[13]	_	_
4-12	306-311	small	abstract[13]	new[13]	_	_
4-13	312-322	proportion	abstract[13]	new[13]	_	_
4-14	323-324	(	_	_	_	_
4-15	325-326	7	abstract[14]	giv[14]	coref	22-8[155_14]
4-16	327-328	%	abstract[14]	giv[14]	_	_
4-17	329-330	)	_	_	_	_
4-18	331-333	of	_	_	_	_
4-19	334-342	patients	person	giv	coref	9-20[62_0]
4-20	343-344	.	_	_	_	_

#Text=This finding is consistent with two 2019 reports by Karacan et al. and Papa et al. , who used recent guidelines for the definition of positive diagnosis as we did .
5-1	345-349	This	abstract[16]	new[16]	_	_
5-2	350-357	finding	abstract[16]	new[16]	_	_
5-3	358-360	is	_	_	_	_
5-4	361-371	consistent	_	_	_	_
5-5	372-376	with	_	_	_	_
5-6	377-380	two	abstract[17]	new[17]	coref	7-2[30_17]
5-7	381-385	2019	abstract[17]	new[17]	_	_
5-8	386-393	reports	abstract[17]	new[17]	_	_
5-9	394-396	by	abstract[17]	new[17]	_	_
5-10	397-404	Karacan	abstract[17]|person	new[17]|new	_	_
5-11	405-407	et	abstract[17]	new[17]	_	_
5-12	408-411	al.	abstract[17]	new[17]	_	_
5-13	412-415	and	abstract[17]	new[17]	_	_
5-14	416-420	Papa	abstract[17]|person[19]	new[17]|new[19]	_	_
5-15	421-423	et	abstract[17]|person[19]	new[17]|new[19]	_	_
5-16	424-427	al.	abstract[17]|person[19]	new[17]|new[19]	_	_
5-17	428-429	,	abstract[17]|person[19]	new[17]|new[19]	_	_
5-18	430-433	who	abstract[17]|person[19]	new[17]|new[19]	_	_
5-19	434-438	used	abstract[17]|person[19]	new[17]|new[19]	_	_
5-20	439-445	recent	abstract[17]|person[19]|abstract[20]	new[17]|new[19]|new[20]	_	_
5-21	446-456	guidelines	abstract[17]|person[19]|abstract[20]	new[17]|new[19]|new[20]	_	_
5-22	457-460	for	abstract[17]|person[19]|abstract[20]	new[17]|new[19]|new[20]	_	_
5-23	461-464	the	abstract[17]|person[19]|abstract[20]|abstract[21]	new[17]|new[19]|new[20]|new[21]	coref	6-5[25_21]
5-24	465-475	definition	abstract[17]|person[19]|abstract[20]|abstract[21]	new[17]|new[19]|new[20]|new[21]	_	_
5-25	476-478	of	abstract[17]|person[19]|abstract[20]|abstract[21]	new[17]|new[19]|new[20]|new[21]	_	_
5-26	479-487	positive	abstract[17]|person[19]|abstract[20]|abstract[21]|abstract[22]	new[17]|new[19]|new[20]|new[21]|new[22]	coref	7-49[44_22]
5-27	488-497	diagnosis	abstract[17]|person[19]|abstract[20]|abstract[21]|abstract[22]	new[17]|new[19]|new[20]|new[21]|new[22]	_	_
5-28	498-500	as	_	_	_	_
5-29	501-503	we	person	giv	ana	8-3
5-30	504-507	did	_	_	_	_
5-31	508-509	.	_	_	_	_

#Text=Three previous studies using a broader definition claimed 19 % , 20 % , and 22 % diagnostic yield .
6-1	510-515	Three	abstract[24]	new[24]	_	_
6-2	516-524	previous	abstract[24]	new[24]	_	_
6-3	525-532	studies	abstract[24]	new[24]	_	_
6-4	533-538	using	abstract[24]	new[24]	_	_
6-5	539-540	a	abstract[24]|abstract[25]	new[24]|giv[25]	coref	8-3[46_25]
6-6	541-548	broader	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
6-7	549-559	definition	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
6-8	560-567	claimed	_	_	_	_
6-9	568-570	19	abstract[26]|abstract[29]	new[26]|new[29]	coref	14-13[106_29]
6-10	571-572	%	abstract[26]|abstract[29]	new[26]|new[29]	_	_
6-11	573-574	,	abstract[29]	new[29]	_	_
6-12	575-577	20	abstract[27]|abstract[29]	new[27]|new[29]	_	_
6-13	578-579	%	abstract[27]|abstract[29]	new[27]|new[29]	_	_
6-14	580-581	,	abstract[29]	new[29]	_	_
6-15	582-585	and	abstract[29]	new[29]	_	_
6-16	586-588	22	abstract[28]|abstract[29]	new[28]|new[29]	_	_
6-17	589-590	%	abstract[28]|abstract[29]	new[28]|new[29]	_	_
6-18	591-601	diagnostic	abstract[29]	new[29]	_	_
6-19	602-607	yield	abstract[29]	new[29]	_	_
6-20	608-609	.	_	_	_	_

#Text=In those reports , for example , frequent variants , such as p. ( Glu148Gln ) ( MEFV ) , p. ( Arg121Gln ) ( TNFRSF1A ) , or p. ( Val198Met ) ( NLRP3 ) , and all known susceptibility factors for inflammation were considered consistent with the diagnosis .
7-1	610-612	In	_	_	_	_
7-2	613-618	those	abstract[30]	giv[30]	_	_
7-3	619-626	reports	abstract[30]	giv[30]	_	_
7-4	627-628	,	_	_	_	_
7-5	629-632	for	_	_	_	_
7-6	633-640	example	_	_	_	_
7-7	641-642	,	_	_	_	_
7-8	643-651	frequent	abstract[31]	new[31]	coref	12-13[92_31]
7-9	652-660	variants	abstract[31]	new[31]	_	_
7-10	661-662	,	abstract[31]	new[31]	_	_
7-11	663-667	such	abstract[31]	new[31]	_	_
7-12	668-670	as	abstract[31]	new[31]	_	_
7-13	671-673	p.	abstract[31]|abstract	new[31]|new	coref	32-18
7-14	674-675	(	_	_	_	_
7-15	676-685	Glu148Gln	abstract	new	appos	7-18
7-16	686-687	)	_	_	_	_
7-17	688-689	(	_	_	_	_
7-18	690-694	MEFV	abstract	giv	coref	10-3[71_0]
7-19	695-696	)	_	_	_	_
7-20	697-698	,	_	_	_	_
7-21	699-701	p.	place	new	_	_
7-22	702-703	(	_	_	_	_
7-23	704-713	Arg121Gln	abstract	new	appos	7-26
7-24	714-715	)	_	_	_	_
7-25	716-717	(	_	_	_	_
7-26	718-726	TNFRSF1A	abstract	giv	_	_
7-27	727-728	)	_	_	_	_
7-28	729-730	,	_	_	_	_
7-29	731-733	or	_	_	_	_
7-30	734-736	p.	place	new	_	_
7-31	737-738	(	_	_	_	_
7-32	739-748	Val198Met	abstract	new	appos	7-35
7-33	749-750	)	_	_	_	_
7-34	751-752	(	_	_	_	_
7-35	753-758	NLRP3	abstract	giv	_	_
7-36	759-760	)	_	_	_	_
7-37	761-762	,	_	_	_	_
7-38	763-766	and	_	_	_	_
7-39	767-770	all	abstract[42]	new[42]	_	_
7-40	771-776	known	abstract[42]	new[42]	_	_
7-41	777-791	susceptibility	abstract|abstract[42]	new|new[42]	_	_
7-42	792-799	factors	abstract[42]	new[42]	_	_
7-43	800-803	for	abstract[42]	new[42]	_	_
7-44	804-816	inflammation	abstract[42]|abstract	new[42]|new	_	_
7-45	817-821	were	_	_	_	_
7-46	822-832	considered	_	_	_	_
7-47	833-843	consistent	_	_	_	_
7-48	844-848	with	_	_	_	_
7-49	849-852	the	abstract[44]	giv[44]	coref	8-22[50_44]
7-50	853-862	diagnosis	abstract[44]	giv[44]	_	_
7-51	863-864	.	_	_	_	_

#Text=Moreover , our definition was more stringent than these four previous studies because we considered that we could not conclude on the diagnosis when the parent ’s DNA was lacking segregation analyses of heterozygous rare VOUS .
8-1	865-873	Moreover	_	_	_	_
8-2	874-875	,	_	_	_	_
8-3	876-879	our	person|abstract[46]	giv|giv[46]	ana	8-14
8-4	880-890	definition	abstract[46]	giv[46]	_	_
8-5	891-894	was	_	_	_	_
8-6	895-899	more	_	_	_	_
8-7	900-909	stringent	_	_	_	_
8-8	910-914	than	_	_	_	_
8-9	915-920	these	abstract[47]	new[47]	_	_
8-10	921-925	four	abstract[47]	new[47]	_	_
8-11	926-934	previous	abstract[47]	new[47]	_	_
8-12	935-942	studies	abstract[47]	new[47]	_	_
8-13	943-950	because	_	_	_	_
8-14	951-953	we	person	giv	ana	8-17
8-15	954-964	considered	_	_	_	_
8-16	965-969	that	_	_	_	_
8-17	970-972	we	person	giv	ana	9-13
8-18	973-978	could	_	_	_	_
8-19	979-982	not	_	_	_	_
8-20	983-991	conclude	_	_	_	_
8-21	992-994	on	_	_	_	_
8-22	995-998	the	abstract[50]	giv[50]	coref	14-14[105_50]
8-23	999-1008	diagnosis	abstract[50]	giv[50]	_	_
8-24	1009-1013	when	_	_	_	_
8-25	1014-1017	the	abstract[52]	new[52]	_	_
8-26	1018-1024	parent	person[51]|abstract[52]	new[51]|new[52]	_	_
8-27	1025-1027	’s	person[51]|abstract[52]	new[51]|new[52]	_	_
8-28	1028-1031	DNA	abstract[52]	new[52]	_	_
8-29	1032-1035	was	_	_	_	_
8-30	1036-1043	lacking	_	_	_	_
8-31	1044-1055	segregation	abstract|abstract[54]	new|new[54]	coref	28-22
8-32	1056-1064	analyses	abstract[54]	new[54]	_	_
8-33	1065-1067	of	abstract[54]	new[54]	_	_
8-34	1068-1080	heterozygous	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-35	1081-1085	rare	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-36	1086-1090	VOUS	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-37	1091-1092	.	_	_	_	_

#Text=The low performance of the AIDs panel might also be explained by our study design that did not include most of the patients with features of FMF , MKD , and DADA2 because they were screened by Sanger sequencing .
9-1	1093-1096	The	abstract[56]	new[56]	coref	17-40[121_56]
9-2	1097-1100	low	abstract[56]	new[56]	_	_
9-3	1101-1112	performance	abstract[56]	new[56]	_	_
9-4	1113-1115	of	abstract[56]	new[56]	_	_
9-5	1116-1119	the	abstract[56]|person[58]	new[56]|new[58]	_	_
9-6	1120-1124	AIDs	abstract[56]|abstract|person[58]	new[56]|giv|new[58]	coref	11-18
9-7	1125-1130	panel	abstract[56]|person[58]	new[56]|new[58]	_	_
9-8	1131-1136	might	_	_	_	_
9-9	1137-1141	also	_	_	_	_
9-10	1142-1144	be	_	_	_	_
9-11	1145-1154	explained	_	_	_	_
9-12	1155-1157	by	_	_	_	_
9-13	1158-1161	our	person|abstract[61]	giv|new[61]	ana|coref	10-23|28-5[194_61]
9-14	1162-1167	study	abstract|abstract[61]	new|new[61]	coref	10-23[76_0]
9-15	1168-1174	design	abstract[61]	new[61]	_	_
9-16	1175-1179	that	abstract[61]	new[61]	_	_
9-17	1180-1183	did	abstract[61]	new[61]	_	_
9-18	1184-1187	not	abstract[61]	new[61]	_	_
9-19	1188-1195	include	abstract[61]	new[61]	_	_
9-20	1196-1200	most	abstract[61]|person[62]	new[61]|giv[62]	ana	9-34[0_62]
9-21	1201-1203	of	abstract[61]|person[62]	new[61]|giv[62]	_	_
9-22	1204-1207	the	abstract[61]|person[62]	new[61]|giv[62]	_	_
9-23	1208-1216	patients	abstract[61]|person[62]	new[61]|giv[62]	_	_
9-24	1217-1221	with	abstract[61]|person[62]	new[61]|giv[62]	_	_
9-25	1222-1230	features	abstract[61]|person[62]|abstract[63]	new[61]|giv[62]|new[63]	coref	25-11[178_63]
9-26	1231-1233	of	abstract[61]|person[62]|abstract[63]	new[61]|giv[62]|new[63]	_	_
9-27	1234-1237	FMF	abstract[61]|person[62]|abstract[63]|abstract	new[61]|giv[62]|new[63]|new	coref	12-4
9-28	1238-1239	,	abstract[61]|person[62]|abstract[63]	new[61]|giv[62]|new[63]	_	_
9-29	1240-1243	MKD	abstract[61]|person[62]|abstract[63]|abstract	new[61]|giv[62]|new[63]|new	_	_
9-30	1244-1245	,	abstract[61]|person[62]|abstract[63]	new[61]|giv[62]|new[63]	_	_
9-31	1246-1249	and	abstract[61]|person[62]|abstract[63]	new[61]|giv[62]|new[63]	_	_
9-32	1250-1255	DADA2	abstract[61]|person[62]|abstract[63]|abstract	new[61]|giv[62]|new[63]|new	_	_
9-33	1256-1263	because	_	_	_	_
9-34	1264-1268	they	person	giv	coref	13-4[96_0]
9-35	1269-1273	were	_	_	_	_
9-36	1274-1282	screened	_	_	_	_
9-37	1283-1285	by	_	_	_	_
9-38	1286-1292	Sanger	person|abstract[69]	new|new[69]	coref	32-49
9-39	1293-1303	sequencing	abstract[69]	new[69]	_	_
9-40	1304-1305	.	_	_	_	_

#Text=Still , the genes MEFV , MVK , and ADA2 remained among the four most frequently involved in the conclusive diagnoses of our study .
10-1	1306-1311	Still	_	_	_	_
10-2	1312-1313	,	_	_	_	_
10-3	1314-1317	the	abstract[70]|abstract[71]	new[70]|giv[71]	coref|coref	13-19[0_71]|30-21[213_70]
10-4	1318-1323	genes	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
10-5	1324-1328	MEFV	abstract[71]	giv[71]	_	_
10-6	1329-1330	,	_	_	_	_
10-7	1331-1334	MVK	abstract	new	coref	32-16
10-8	1335-1336	,	_	_	_	_
10-9	1337-1340	and	_	_	_	_
10-10	1341-1345	ADA2	abstract	new	_	_
10-11	1346-1354	remained	_	_	_	_
10-12	1355-1360	among	_	_	_	_
10-13	1361-1364	the	_	_	_	_
10-14	1365-1369	four	_	_	_	_
10-15	1370-1374	most	_	_	_	_
10-16	1375-1385	frequently	_	_	_	_
10-17	1386-1394	involved	_	_	_	_
10-18	1395-1397	in	_	_	_	_
10-19	1398-1401	the	abstract[74]	new[74]	_	_
10-20	1402-1412	conclusive	abstract[74]	new[74]	_	_
10-21	1413-1422	diagnoses	abstract[74]	new[74]	_	_
10-22	1423-1425	of	abstract[74]	new[74]	_	_
10-23	1426-1429	our	abstract[74]|person|abstract[76]	new[74]|giv|giv[76]	ana|coref	14-2|23-3[159_76]
10-24	1430-1435	study	abstract[74]|abstract[76]	new[74]|giv[76]	_	_
10-25	1436-1437	.	_	_	_	_

#Text=This observation possibly stems from a better detection by NGS of the new molecular mechanisms involved in AIDs ( mosaicism , CNVs ) and better information on these three diseases because they are among the best-described AIDs .
11-1	1438-1442	This	abstract[77]	new[77]	_	_
11-2	1443-1454	observation	abstract[77]	new[77]	_	_
11-3	1455-1463	possibly	_	_	_	_
11-4	1464-1469	stems	_	_	_	_
11-5	1470-1474	from	_	_	_	_
11-6	1475-1476	a	event[78]	new[78]	_	_
11-7	1477-1483	better	event[78]	new[78]	_	_
11-8	1484-1493	detection	event[78]	new[78]	_	_
11-9	1494-1496	by	event[78]	new[78]	_	_
11-10	1497-1500	NGS	event[78]|abstract	new[78]|giv	coref	18-5
11-11	1501-1503	of	event[78]	new[78]	_	_
11-12	1504-1507	the	event[78]|abstract[80]	new[78]|new[80]	appos	11-20[0_80]
11-13	1508-1511	new	event[78]|abstract[80]	new[78]|new[80]	_	_
11-14	1512-1521	molecular	event[78]|abstract[80]	new[78]|new[80]	_	_
11-15	1522-1532	mechanisms	event[78]|abstract[80]	new[78]|new[80]	_	_
11-16	1533-1541	involved	event[78]|abstract[80]	new[78]|new[80]	_	_
11-17	1542-1544	in	event[78]|abstract[80]	new[78]|new[80]	_	_
11-18	1545-1549	AIDs	event[78]|abstract[80]|abstract	new[78]|new[80]|giv	coref	18-26
11-19	1550-1551	(	_	_	_	_
11-20	1552-1561	mosaicism	abstract|abstract[83]	giv|giv[83]	appos|appos	11-20[83_0]|11-22[0_83]
11-21	1562-1563	,	abstract[83]	giv[83]	_	_
11-22	1564-1568	CNVs	abstract[83]|abstract	giv[83]|giv	coref	30-24[215_0]
11-23	1569-1570	)	_	_	_	_
11-24	1571-1574	and	_	_	_	_
11-25	1575-1581	better	abstract[85]	new[85]	_	_
11-26	1582-1593	information	abstract[85]	new[85]	_	_
11-27	1594-1596	on	abstract[85]	new[85]	_	_
11-28	1597-1602	these	abstract[85]|abstract[86]	new[85]|new[86]	ana	11-32[0_86]
11-29	1603-1608	three	abstract[85]|abstract[86]	new[85]|new[86]	_	_
11-30	1609-1617	diseases	abstract[85]|abstract[86]	new[85]|new[86]	_	_
11-31	1618-1625	because	_	_	_	_
11-32	1626-1630	they	abstract	giv	_	_
11-33	1631-1634	are	_	_	_	_
11-34	1635-1640	among	_	_	_	_
11-35	1641-1644	the	abstract[88]	new[88]	_	_
11-36	1645-1659	best-described	abstract[88]	new[88]	_	_
11-37	1660-1664	AIDs	abstract[88]	new[88]	_	_
11-38	1665-1666	.	_	_	_	_

#Text=In addition , FMF is now recognized as a disease caused by gain-of-function variants with a dosage effect rather than a purely recessive condition .
12-1	1667-1669	In	_	_	_	_
12-2	1670-1678	addition	_	_	_	_
12-3	1679-1680	,	_	_	_	_
12-4	1681-1684	FMF	abstract	giv	_	_
12-5	1685-1687	is	_	_	_	_
12-6	1688-1691	now	_	_	_	_
12-7	1692-1702	recognized	_	_	_	_
12-8	1703-1705	as	_	_	_	_
12-9	1706-1707	a	abstract[90]	giv[90]	_	_
12-10	1708-1715	disease	abstract[90]	giv[90]	_	_
12-11	1716-1722	caused	abstract[90]	giv[90]	_	_
12-12	1723-1725	by	abstract[90]	giv[90]	_	_
12-13	1726-1742	gain-of-function	abstract[90]|abstract|abstract[92]	giv[90]|new|giv[92]	coref	32-29[237_92]
12-14	1743-1751	variants	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-15	1752-1756	with	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-16	1757-1758	a	abstract[90]|abstract[92]|abstract[94]	giv[90]|giv[92]|new[94]	_	_
12-17	1759-1765	dosage	abstract[90]|abstract[92]|substance|abstract[94]	giv[90]|giv[92]|new|new[94]	_	_
12-18	1766-1772	effect	abstract[90]|abstract[92]|abstract[94]	giv[90]|giv[92]|new[94]	_	_
12-19	1773-1779	rather	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-20	1780-1784	than	abstract[90]|abstract[92]	giv[90]|giv[92]	_	_
12-21	1785-1786	a	abstract[90]|abstract[92]|abstract[95]	giv[90]|giv[92]|new[95]	coref	13-12[98_95]
12-22	1787-1793	purely	abstract[90]|abstract[92]|abstract[95]	giv[90]|giv[92]|new[95]	_	_
12-23	1794-1803	recessive	abstract[90]|abstract[92]|abstract[95]	giv[90]|giv[92]|new[95]	_	_
12-24	1804-1813	condition	abstract[90]|abstract[92]|abstract[95]	giv[90]|giv[92]|new[95]	_	_
12-25	1814-1815	.	_	_	_	_

#Text=For one-third of the patients with one heterozygous pathogenic variant in a recessive condition , the gene was MEFV .
13-1	1816-1819	For	_	_	_	_
13-2	1820-1829	one-third	_	_	_	_
13-3	1830-1832	of	_	_	_	_
13-4	1833-1836	the	person[96]	giv[96]	coref	17-20[114_96]
13-5	1837-1845	patients	person[96]	giv[96]	_	_
13-6	1846-1850	with	person[96]	giv[96]	_	_
13-7	1851-1854	one	person[96]|abstract[97]	giv[96]|new[97]	coref	14-8[104_97]
13-8	1855-1867	heterozygous	person[96]|abstract[97]	giv[96]|new[97]	_	_
13-9	1868-1878	pathogenic	person[96]|abstract[97]	giv[96]|new[97]	_	_
13-10	1879-1886	variant	person[96]|abstract[97]	giv[96]|new[97]	_	_
13-11	1887-1889	in	person[96]|abstract[97]	giv[96]|new[97]	_	_
13-12	1890-1891	a	person[96]|abstract[97]|abstract[98]	giv[96]|new[97]|giv[98]	_	_
13-13	1892-1901	recessive	person[96]|abstract[97]|abstract[98]	giv[96]|new[97]|giv[98]	_	_
13-14	1902-1911	condition	person[96]|abstract[97]|abstract[98]	giv[96]|new[97]|giv[98]	_	_
13-15	1912-1913	,	_	_	_	_
13-16	1914-1917	the	abstract[99]	new[99]	_	_
13-17	1918-1922	gene	abstract[99]	new[99]	_	_
13-18	1923-1926	was	_	_	_	_
13-19	1927-1931	MEFV	abstract	giv	coref	14-9
13-20	1932-1933	.	_	_	_	_

#Text=If we had included heterozygous carriers of a MEFV pathogenic variant , the genetic diagnosis yield would have improved up to 10 % (
14-1	1934-1936	If	_	_	_	_
14-2	1937-1939	we	person	giv	ana	17-24
14-3	1940-1943	had	_	_	_	_
14-4	1944-1952	included	_	_	_	_
14-5	1953-1965	heterozygous	animal[102]	new[102]	_	_
14-6	1966-1974	carriers	animal[102]	new[102]	_	_
14-7	1975-1977	of	animal[102]	new[102]	_	_
14-8	1978-1979	a	animal[102]|abstract[104]	new[102]|giv[104]	_	_
14-9	1980-1984	MEFV	animal[102]|abstract|abstract[104]	new[102]|giv|giv[104]	_	_
14-10	1985-1995	pathogenic	animal[102]|abstract[104]	new[102]|giv[104]	_	_
14-11	1996-2003	variant	animal[102]|abstract[104]	new[102]|giv[104]	_	_
14-12	2004-2005	,	_	_	_	_
14-13	2006-2009	the	abstract[106]	giv[106]	_	_
14-14	2010-2017	genetic	abstract[105]|abstract[106]	giv[105]|giv[106]	coref	25-5[176_105]
14-15	2018-2027	diagnosis	abstract[105]|abstract[106]	giv[105]|giv[106]	_	_
14-16	2028-2033	yield	abstract[106]	giv[106]	_	_
14-17	2034-2039	would	_	_	_	_
14-18	2040-2044	have	_	_	_	_
14-19	2045-2053	improved	_	_	_	_
14-20	2054-2056	up	abstract[107]	new[107]	_	_
14-21	2057-2059	to	abstract[107]	new[107]	_	_
14-22	2060-2062	10	abstract[107]	new[107]	_	_
14-23	2063-2064	%	abstract[107]	new[107]	_	_
14-24	2065-2066	(	_	_	_	_

#Text=Figure 2
15-1	2067-2073	Figure	abstract[108]	new[108]	_	_
15-2	2074-2075	2	abstract[108]	new[108]	_	_

#Text=) .
16-1	2076-2077	)	_	_	_	_
16-2	2078-2079	.	_	_	_	_

#Text=In an attempt to find a cause that could explain the low rate of genetic confirmation using panels in the patients referred to us , we wondered whether validation of the request by a specialized reference center could improve this performance .
17-1	2080-2082	In	_	_	_	_
17-2	2083-2085	an	event[109]	new[109]	_	_
17-3	2086-2093	attempt	event[109]	new[109]	_	_
17-4	2094-2096	to	event[109]	new[109]	_	_
17-5	2097-2101	find	event[109]	new[109]	_	_
17-6	2102-2103	a	event[109]|abstract[110]	new[109]|new[110]	_	_
17-7	2104-2109	cause	event[109]|abstract[110]	new[109]|new[110]	_	_
17-8	2110-2114	that	event[109]|abstract[110]	new[109]|new[110]	_	_
17-9	2115-2120	could	event[109]|abstract[110]	new[109]|new[110]	_	_
17-10	2121-2128	explain	event[109]|abstract[110]	new[109]|new[110]	_	_
17-11	2129-2132	the	event[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
17-12	2133-2136	low	event[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
17-13	2137-2141	rate	event[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
17-14	2142-2144	of	event[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
17-15	2145-2152	genetic	event[109]|abstract[110]|abstract[111]|abstract[112]	new[109]|new[110]|new[111]|giv[112]	_	_
17-16	2153-2165	confirmation	event[109]|abstract[110]|abstract[111]|abstract[112]	new[109]|new[110]|new[111]|giv[112]	_	_
17-17	2166-2171	using	event[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
17-18	2172-2178	panels	event[109]|abstract[110]|abstract[111]|object	new[109]|new[110]|new[111]|new	coref	27-12[190_0]
17-19	2179-2181	in	event[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
17-20	2182-2185	the	event[109]|abstract[110]|abstract[111]|person[114]	new[109]|new[110]|new[111]|giv[114]	coref	18-24[129_114]
17-21	2186-2194	patients	event[109]|abstract[110]|abstract[111]|person[114]	new[109]|new[110]|new[111]|giv[114]	_	_
17-22	2195-2203	referred	event[109]|abstract[110]|abstract[111]|person[114]	new[109]|new[110]|new[111]|giv[114]	_	_
17-23	2204-2206	to	event[109]|abstract[110]|abstract[111]|person[114]	new[109]|new[110]|new[111]|giv[114]	_	_
17-24	2207-2209	us	event[109]|abstract[110]|abstract[111]|person[114]|person	new[109]|new[110]|new[111]|giv[114]|giv	ana	17-26
17-25	2210-2211	,	_	_	_	_
17-26	2212-2214	we	person	giv	ana	20-1
17-27	2215-2223	wondered	_	_	_	_
17-28	2224-2231	whether	_	_	_	_
17-29	2232-2242	validation	event[117]	new[117]	_	_
17-30	2243-2245	of	event[117]	new[117]	_	_
17-31	2246-2249	the	event[117]|event[118]	new[117]|new[118]	_	_
17-32	2250-2257	request	event[117]|event[118]	new[117]|new[118]	_	_
17-33	2258-2260	by	event[117]	new[117]	_	_
17-34	2261-2262	a	event[117]|organization[120]	new[117]|new[120]	coref	24-3[169_120]
17-35	2263-2274	specialized	event[117]|organization[120]	new[117]|new[120]	_	_
17-36	2275-2284	reference	event[117]|person|organization[120]	new[117]|new|new[120]	coref	19-2
17-37	2285-2291	center	event[117]|organization[120]	new[117]|new[120]	_	_
17-38	2292-2297	could	_	_	_	_
17-39	2298-2305	improve	_	_	_	_
17-40	2306-2310	this	abstract[121]	giv[121]	_	_
17-41	2311-2322	performance	abstract[121]	giv[121]	_	_
17-42	2323-2324	.	_	_	_	_

#Text=The success of the NGS approach was suggested to rely on its use in the context of a highly specialized clinical service for patients with AIDs .
18-1	2325-2328	The	abstract[122]	new[122]	_	_
18-2	2329-2336	success	abstract[122]	new[122]	_	_
18-3	2337-2339	of	abstract[122]	new[122]	_	_
18-4	2340-2343	the	abstract[122]|abstract[124]	new[122]|giv[124]	ana	18-12[0_124]
18-5	2344-2347	NGS	abstract[122]|abstract|abstract[124]	new[122]|giv|giv[124]	coref	23-26
18-6	2348-2356	approach	abstract[122]|abstract[124]	new[122]|giv[124]	_	_
18-7	2357-2360	was	_	_	_	_
18-8	2361-2370	suggested	_	_	_	_
18-9	2371-2373	to	_	_	_	_
18-10	2374-2378	rely	_	_	_	_
18-11	2379-2381	on	_	_	_	_
18-12	2382-2385	its	abstract|abstract[126]	giv|new[126]	_	_
18-13	2386-2389	use	abstract[126]	new[126]	_	_
18-14	2390-2392	in	abstract[126]	new[126]	_	_
18-15	2393-2396	the	abstract[126]|abstract[127]	new[126]|new[127]	_	_
18-16	2397-2404	context	abstract[126]|abstract[127]	new[126]|new[127]	_	_
18-17	2405-2407	of	abstract[126]|abstract[127]	new[126]|new[127]	_	_
18-18	2408-2409	a	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
18-19	2410-2416	highly	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
18-20	2417-2428	specialized	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
18-21	2429-2437	clinical	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
18-22	2438-2445	service	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
18-23	2446-2449	for	abstract[126]|abstract[127]|abstract[128]	new[126]|new[127]|new[128]	_	_
18-24	2450-2458	patients	abstract[126]|abstract[127]|abstract[128]|person[129]	new[126]|new[127]|new[128]|giv[129]	coref	20-10[142_129]
18-25	2459-2463	with	abstract[126]|abstract[127]|abstract[128]|person[129]	new[126]|new[127]|new[128]|giv[129]	_	_
18-26	2464-2468	AIDs	abstract[126]|abstract[127]|abstract[128]|person[129]|abstract	new[126]|new[127]|new[128]|giv[129]|giv	coref	20-11
18-27	2469-2470	.	_	_	_	_

#Text=National reference centers and networks cover all the expertise necessary for patient care and operational management and efficiency .
19-1	2471-2479	National	place[132]	new[132]	coref	20-16[145_132]
19-2	2480-2489	reference	person|place[132]	giv|new[132]	coref	20-16
19-3	2490-2497	centers	place[132]	new[132]	_	_
19-4	2498-2501	and	_	_	_	_
19-5	2502-2510	networks	place	new	_	_
19-6	2511-2516	cover	_	_	_	_
19-7	2517-2520	all	abstract[134]	new[134]	_	_
19-8	2521-2524	the	abstract[134]	new[134]	_	_
19-9	2525-2534	expertise	abstract[134]	new[134]	_	_
19-10	2535-2544	necessary	abstract[134]	new[134]	_	_
19-11	2545-2548	for	abstract[134]	new[134]	_	_
19-12	2549-2556	patient	abstract[134]|abstract[135]	new[134]|new[135]	_	_
19-13	2557-2561	care	abstract[134]|abstract[135]	new[134]|new[135]	_	_
19-14	2562-2565	and	abstract[134]	new[134]	_	_
19-15	2566-2577	operational	abstract[134]|abstract[136]	new[134]|new[136]	_	_
19-16	2578-2588	management	abstract[134]|abstract[136]	new[134]|new[136]	_	_
19-17	2589-2592	and	abstract[134]	new[134]	_	_
19-18	2593-2603	efficiency	abstract[134]|abstract	new[134]|new	_	_
19-19	2604-2605	.	_	_	_	_

#Text=We established a pre-requisite for a systematic evaluation of undifferentiated AIDs patients by clinicians from reference centers .
20-1	2606-2608	We	person	giv	ana	23-3
20-2	2609-2620	established	_	_	_	_
20-3	2621-2622	a	place[139]	new[139]	ana	22-1[0_139]
20-4	2623-2636	pre-requisite	place[139]	new[139]	_	_
20-5	2637-2640	for	place[139]	new[139]	_	_
20-6	2641-2642	a	place[139]|event[140]	new[139]|new[140]	ana	21-1[0_140]
20-7	2643-2653	systematic	place[139]|event[140]	new[139]|new[140]	_	_
20-8	2654-2664	evaluation	place[139]|event[140]	new[139]|new[140]	_	_
20-9	2665-2667	of	place[139]|event[140]	new[139]|new[140]	_	_
20-10	2668-2684	undifferentiated	place[139]|event[140]|person[142]	new[139]|new[140]|giv[142]	coref	21-17[151_142]
20-11	2685-2689	AIDs	place[139]|event[140]|abstract|person[142]	new[139]|new[140]|giv|giv[142]	coref	26-24
20-12	2690-2698	patients	place[139]|event[140]|person[142]	new[139]|new[140]|giv[142]	_	_
20-13	2699-2701	by	_	_	_	_
20-14	2702-2712	clinicians	person[143]	new[143]	coref	31-10[0_143]
20-15	2713-2717	from	person[143]	new[143]	_	_
20-16	2718-2727	reference	person[143]|person|place[145]	new[143]|giv|giv[145]	coref|coref	21-8[148_145]|24-4
20-17	2728-2735	centers	person[143]|place[145]	new[143]|giv[145]	_	_
20-18	2736-2737	.	_	_	_	_

#Text=It is possible that many doctors from non-reference centers could not find the time to present their patients to MSM .
21-1	2738-2740	It	event	giv	_	_
21-2	2741-2743	is	_	_	_	_
21-3	2744-2752	possible	_	_	_	_
21-4	2753-2757	that	_	_	_	_
21-5	2758-2762	many	person[147]	new[147]	ana	21-17[0_147]
21-6	2763-2770	doctors	person[147]	new[147]	_	_
21-7	2771-2775	from	person[147]	new[147]	_	_
21-8	2776-2789	non-reference	person[147]|place[148]	new[147]|giv[148]	coref	22-14[157_148]
21-9	2790-2797	centers	person[147]|place[148]	new[147]|giv[148]	_	_
21-10	2798-2803	could	_	_	_	_
21-11	2804-2807	not	_	_	_	_
21-12	2808-2812	find	_	_	_	_
21-13	2813-2816	the	time[149]	new[149]	coref	31-14[225_149]
21-14	2817-2821	time	time[149]	new[149]	_	_
21-15	2822-2824	to	time[149]	new[149]	_	_
21-16	2825-2832	present	time[149]	new[149]	_	_
21-17	2833-2838	their	time[149]|person|person[151]	new[149]|giv|giv[151]	coref	22-11[156_151]
21-18	2839-2847	patients	time[149]|person[151]	new[149]|giv[151]	_	_
21-19	2848-2850	to	time[149]	new[149]	_	_
21-20	2851-2854	MSM	time[149]|organization	new[149]|new	coref	33-5[252_0]
21-21	2855-2856	.	_	_	_	_

#Text=This certainly accounts for the decrease in the proportion of patients referred by the non-reference centers .
22-1	2857-2861	This	place	giv	_	_
22-2	2862-2871	certainly	_	_	_	_
22-3	2872-2880	accounts	_	_	_	_
22-4	2881-2884	for	_	_	_	_
22-5	2885-2888	the	event[154]	new[154]	_	_
22-6	2889-2897	decrease	event[154]	new[154]	_	_
22-7	2898-2900	in	event[154]	new[154]	_	_
22-8	2901-2904	the	event[154]|abstract[155]	new[154]|giv[155]	_	_
22-9	2905-2915	proportion	event[154]|abstract[155]	new[154]|giv[155]	_	_
22-10	2916-2918	of	event[154]|abstract[155]	new[154]|giv[155]	_	_
22-11	2919-2927	patients	event[154]|abstract[155]|person[156]	new[154]|giv[155]|giv[156]	coref	25-2[175_156]
22-12	2928-2936	referred	event[154]|abstract[155]|person[156]	new[154]|giv[155]|giv[156]	_	_
22-13	2937-2939	by	event[154]|abstract[155]|person[156]	new[154]|giv[155]|giv[156]	_	_
22-14	2940-2943	the	event[154]|abstract[155]|person[156]|place[157]	new[154]|giv[155]|giv[156]|giv[157]	coref	34-4[258_157]
22-15	2944-2957	non-reference	event[154]|abstract[155]|person[156]|place[157]	new[154]|giv[155]|giv[156]|giv[157]	_	_
22-16	2958-2965	centers	event[154]|abstract[155]|person[156]|place[157]	new[154]|giv[155]|giv[156]|giv[157]	_	_
22-17	2966-2967	.	_	_	_	_

#Text=However , our study showed that this strategy resulted in a better clinical filter for ordering genetic tests and almost doubled the performance of our NGS strategy .
23-1	2968-2975	However	_	_	_	_
23-2	2976-2977	,	_	_	_	_
23-3	2978-2981	our	person|abstract[159]	giv|giv[159]	ana|coref	23-25|28-6[0_159]
23-4	2982-2987	study	abstract[159]	giv[159]	_	_
23-5	2988-2994	showed	_	_	_	_
23-6	2995-2999	that	_	_	_	_
23-7	3000-3004	this	abstract[160]	new[160]	coref	23-25[166_160]
23-8	3005-3013	strategy	abstract[160]	new[160]	_	_
23-9	3014-3022	resulted	abstract	new	coref	26-1[179_0]
23-10	3023-3025	in	_	_	_	_
23-11	3026-3027	a	abstract[161]	new[161]	_	_
23-12	3028-3034	better	abstract[161]	new[161]	_	_
23-13	3035-3043	clinical	abstract[161]	new[161]	_	_
23-14	3044-3050	filter	abstract[161]	new[161]	_	_
23-15	3051-3054	for	abstract[161]	new[161]	_	_
23-16	3055-3063	ordering	abstract[161]	new[161]	_	_
23-17	3064-3071	genetic	abstract[161]|abstract[162]	new[161]|new[162]	coref	24-21[173_162]
23-18	3072-3077	tests	abstract[161]|abstract[162]	new[161]|new[162]	_	_
23-19	3078-3081	and	_	_	_	_
23-20	3082-3088	almost	_	_	_	_
23-21	3089-3096	doubled	_	_	_	_
23-22	3097-3100	the	abstract[163]	new[163]	_	_
23-23	3101-3112	performance	abstract[163]	new[163]	_	_
23-24	3113-3115	of	abstract[163]	new[163]	_	_
23-25	3116-3119	our	abstract[163]|person|abstract[166]	new[163]|giv|giv[166]	ana|coref	24-3|33-10[253_166]
23-26	3120-3123	NGS	abstract[163]|abstract|abstract[166]	new[163]|giv|giv[166]	coref	27-12
23-27	3124-3132	strategy	abstract[163]|abstract[166]	new[163]|giv[166]	_	_
23-28	3133-3134	.	_	_	_	_

#Text=Also , our reference center recently offered a diagnostic checklist to guide practitioners who may suspect an AID for ordering genetic tests .
24-1	3135-3139	Also	_	_	_	_
24-2	3140-3141	,	_	_	_	_
24-3	3142-3145	our	person|organization[169]	giv|giv[169]	ana|coref	25-2|36-9[268_169]
24-4	3146-3155	reference	person|organization[169]	giv|giv[169]	coref	34-5
24-5	3156-3162	center	organization[169]	giv[169]	_	_
24-6	3163-3171	recently	_	_	_	_
24-7	3172-3179	offered	_	_	_	_
24-8	3180-3181	a	abstract[170]	new[170]	_	_
24-9	3182-3192	diagnostic	abstract[170]	new[170]	_	_
24-10	3193-3202	checklist	abstract[170]	new[170]	_	_
24-11	3203-3205	to	_	_	_	_
24-12	3206-3211	guide	_	_	_	_
24-13	3212-3225	practitioners	person[171]	new[171]	_	_
24-14	3226-3229	who	person[171]	new[171]	_	_
24-15	3230-3233	may	person[171]	new[171]	_	_
24-16	3234-3241	suspect	person[171]	new[171]	_	_
24-17	3242-3244	an	person[171]|abstract[172]	new[171]|new[172]	coref	25-9[0_172]
24-18	3245-3248	AID	person[171]|abstract[172]	new[171]|new[172]	_	_
24-19	3249-3252	for	person[171]|abstract[172]	new[171]|new[172]	_	_
24-20	3253-3261	ordering	person[171]|abstract[172]	new[171]|new[172]	_	_
24-21	3262-3269	genetic	person[171]|abstract[172]|abstract[173]	new[171]|new[172]|giv[173]	_	_
24-22	3270-3275	tests	person[171]|abstract[172]|abstract[173]	new[171]|new[172]|giv[173]	_	_
24-23	3276-3277	.	_	_	_	_

#Text=In our patients with a conclusive diagnosis of AID , the main features identified were mucocutaneous , articular , and gastro-intestinal .
25-1	3278-3280	In	_	_	_	_
25-2	3281-3284	our	person|person[175]	giv|giv[175]	ana|coref	27-1|28-11[196_175]
25-3	3285-3293	patients	person[175]	giv[175]	_	_
25-4	3294-3298	with	person[175]	giv[175]	_	_
25-5	3299-3300	a	person[175]|abstract[176]	giv[175]|giv[176]	coref	30-34[218_176]
25-6	3301-3311	conclusive	person[175]|abstract[176]	giv[175]|giv[176]	_	_
25-7	3312-3321	diagnosis	person[175]|abstract[176]	giv[175]|giv[176]	_	_
25-8	3322-3324	of	person[175]|abstract[176]	giv[175]|giv[176]	_	_
25-9	3325-3328	AID	person[175]|abstract[176]|abstract	giv[175]|giv[176]|giv	coref	34-19[260_0]
25-10	3329-3330	,	_	_	_	_
25-11	3331-3334	the	abstract[178]	giv[178]	_	_
25-12	3335-3339	main	abstract[178]	giv[178]	_	_
25-13	3340-3348	features	abstract[178]	giv[178]	_	_
25-14	3349-3359	identified	abstract[178]	giv[178]	_	_
25-15	3360-3364	were	_	_	_	_
25-16	3365-3378	mucocutaneous	_	_	_	_
25-17	3379-3380	,	_	_	_	_
25-18	3381-3390	articular	_	_	_	_
25-19	3391-3392	,	_	_	_	_
25-20	3393-3396	and	_	_	_	_
25-21	3397-3414	gastro-intestinal	_	_	_	_
25-22	3415-3416	.	_	_	_	_

#Text=This result reflects daily practice because the cutaneous/mucosal , digestive tract , and musculoskeletal systems are the three most common systems involved in AIDs .
26-1	3417-3421	This	abstract[179]	new[179]	_	_
26-2	3422-3428	result	abstract[179]	new[179]	_	_
26-3	3429-3437	reflects	_	_	_	_
26-4	3438-3443	daily	event[180]	new[180]	_	_
26-5	3444-3452	practice	event[180]	new[180]	_	_
26-6	3453-3460	because	_	_	_	_
26-7	3461-3464	the	abstract[181]	new[181]	_	_
26-8	3465-3482	cutaneous/mucosal	abstract[181]	new[181]	_	_
26-9	3483-3484	,	_	_	_	_
26-10	3485-3494	digestive	object[182]	new[182]	_	_
26-11	3495-3500	tract	object[182]	new[182]	_	_
26-12	3501-3502	,	_	_	_	_
26-13	3503-3506	and	_	_	_	_
26-14	3507-3522	musculoskeletal	abstract[183]	new[183]	coref	26-17[184_183]
26-15	3523-3530	systems	abstract[183]	new[183]	_	_
26-16	3531-3534	are	_	_	_	_
26-17	3535-3538	the	abstract[184]	giv[184]	_	_
26-18	3539-3544	three	abstract[184]	giv[184]	_	_
26-19	3545-3549	most	abstract[184]	giv[184]	_	_
26-20	3550-3556	common	abstract[184]	giv[184]	_	_
26-21	3557-3564	systems	abstract[184]	giv[184]	_	_
26-22	3565-3573	involved	abstract[184]	giv[184]	_	_
26-23	3574-3576	in	abstract[184]	giv[184]	_	_
26-24	3577-3581	AIDs	abstract[184]|abstract	giv[184]|giv	coref	27-15[191_0]
26-25	3582-3583	.	_	_	_	_

#Text=We cannot rule out a relative underestimation of the potential of NGS panels for AIDs in general .
27-1	3584-3586	We	person	giv	ana	28-5
27-2	3587-3593	cannot	_	_	_	_
27-3	3594-3598	rule	_	_	_	_
27-4	3599-3602	out	_	_	_	_
27-5	3603-3604	a	abstract[187]	new[187]	_	_
27-6	3605-3613	relative	abstract[187]	new[187]	_	_
27-7	3614-3629	underestimation	abstract[187]	new[187]	_	_
27-8	3630-3632	of	abstract[187]	new[187]	_	_
27-9	3633-3636	the	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-10	3637-3646	potential	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-11	3647-3649	of	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-12	3650-3653	NGS	abstract[187]|abstract[188]|abstract|object[190]	new[187]|new[188]|giv|giv[190]	coref	28-20
27-13	3654-3660	panels	abstract[187]|abstract[188]|object[190]	new[187]|new[188]|giv[190]	_	_
27-14	3661-3664	for	abstract[187]|abstract[188]|object[190]	new[187]|new[188]|giv[190]	_	_
27-15	3665-3669	AIDs	abstract[187]|abstract[188]|object[190]|abstract[191]	new[187]|new[188]|giv[190]|giv[191]	ana	28-9[195_191]
27-16	3670-3672	in	abstract[187]|abstract[188]|object[190]|abstract[191]	new[187]|new[188]|giv[190]|giv[191]	_	_
27-17	3673-3680	general	abstract[187]|abstract[188]|object[190]|abstract[191]	new[187]|new[188]|giv[190]|giv[191]	_	_
27-18	3681-3682	.	_	_	_	_

#Text=Indeed , because of our study design , some of the patients or their relatives were not available for NGS or segregation analysis .
28-1	3683-3689	Indeed	_	_	_	_
28-2	3690-3691	,	_	_	_	_
28-3	3692-3699	because	_	_	_	_
28-4	3700-3702	of	_	_	_	_
28-5	3703-3706	our	person|abstract[194]	giv|giv[194]	ana	29-3
28-6	3707-3712	study	abstract|abstract[194]	giv|giv[194]	_	_
28-7	3713-3719	design	abstract[194]	giv[194]	_	_
28-8	3720-3721	,	_	_	_	_
28-9	3722-3726	some	abstract[195]	giv[195]	coref	30-28[0_195]
28-10	3727-3729	of	abstract[195]	giv[195]	_	_
28-11	3730-3733	the	abstract[195]|person[196]|person[197]	giv[195]|giv[196]|giv[197]	coref|ana	28-11[197_196]|28-14[0_197]
28-12	3734-3742	patients	abstract[195]|person[196]|person[197]	giv[195]|giv[196]|giv[197]	_	_
28-13	3743-3745	or	abstract[195]|person[197]	giv[195]|giv[197]	_	_
28-14	3746-3751	their	abstract[195]|person[197]|person|person[199]	giv[195]|giv[197]|giv|new[199]	coref	32-32[238_0]
28-15	3752-3761	relatives	abstract[195]|person[197]|person[199]	giv[195]|giv[197]|new[199]	_	_
28-16	3762-3766	were	_	_	_	_
28-17	3767-3770	not	_	_	_	_
28-18	3771-3780	available	_	_	_	_
28-19	3781-3784	for	_	_	_	_
28-20	3785-3788	NGS	abstract	giv	coref	29-13
28-21	3789-3791	or	_	_	_	_
28-22	3792-3803	segregation	abstract|abstract[202]	giv|new[202]	_	_
28-23	3804-3812	analysis	abstract[202]	new[202]	_	_
28-24	3813-3814	.	_	_	_	_

#Text=However , our aim was not to evaluate the exact performance of NGS but to find ways to improve it .
29-1	3815-3822	However	_	_	_	_
29-2	3823-3824	,	_	_	_	_
29-3	3825-3828	our	person|abstract[204]	giv|new[204]	ana	30-8
29-4	3829-3832	aim	abstract[204]	new[204]	_	_
29-5	3833-3836	was	_	_	_	_
29-6	3837-3840	not	_	_	_	_
29-7	3841-3843	to	_	_	_	_
29-8	3844-3852	evaluate	_	_	_	_
29-9	3853-3856	the	abstract[205]	new[205]	_	_
29-10	3857-3862	exact	abstract[205]	new[205]	_	_
29-11	3863-3874	performance	abstract[205]	new[205]	_	_
29-12	3875-3877	of	abstract[205]	new[205]	_	_
29-13	3878-3881	NGS	abstract[205]|abstract	new[205]|giv	ana	29-20
29-14	3882-3885	but	_	_	_	_
29-15	3886-3888	to	_	_	_	_
29-16	3889-3893	find	_	_	_	_
29-17	3894-3898	ways	abstract	new	_	_
29-18	3899-3901	to	_	_	_	_
29-19	3902-3909	improve	_	_	_	_
29-20	3910-3912	it	abstract	giv	coref	35-22[265_0]
29-21	3913-3914	.	_	_	_	_

#Text=In addition to the successful clinical option we demonstrated here , it is easy to predict the upcoming discovery of new genes or molecular mechanisms involved in AIDs that will continue to revolutionize our routine genetic diagnosis .
30-1	3915-3917	In	_	_	_	_
30-2	3918-3926	addition	_	_	_	_
30-3	3927-3929	to	_	_	_	_
30-4	3930-3933	the	abstract[209]	new[209]	ana	30-12[0_209]
30-5	3934-3944	successful	abstract[209]	new[209]	_	_
30-6	3945-3953	clinical	abstract[209]	new[209]	_	_
30-7	3954-3960	option	abstract[209]	new[209]	_	_
30-8	3961-3963	we	abstract[209]|person	new[209]|giv	ana	30-34
30-9	3964-3976	demonstrated	abstract[209]	new[209]	_	_
30-10	3977-3981	here	abstract[209]	new[209]	_	_
30-11	3982-3983	,	_	_	_	_
30-12	3984-3986	it	abstract	giv	_	_
30-13	3987-3989	is	_	_	_	_
30-14	3990-3994	easy	_	_	_	_
30-15	3995-3997	to	_	_	_	_
30-16	3998-4005	predict	_	_	_	_
30-17	4006-4009	the	event[212]	new[212]	_	_
30-18	4010-4018	upcoming	event[212]	new[212]	_	_
30-19	4019-4028	discovery	event[212]	new[212]	_	_
30-20	4029-4031	of	event[212]	new[212]	_	_
30-21	4032-4035	new	event[212]|abstract[213]|abstract[214]	new[212]|giv[213]|giv[214]	coref|coref	30-21[214_213]|32-68[248_214]
30-22	4036-4041	genes	event[212]|abstract[213]|abstract[214]	new[212]|giv[213]|giv[214]	_	_
30-23	4042-4044	or	event[212]|abstract[214]	new[212]|giv[214]	_	_
30-24	4045-4054	molecular	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-25	4055-4065	mechanisms	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-26	4066-4074	involved	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-27	4075-4077	in	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-28	4078-4082	AIDs	event[212]|abstract[214]|abstract[215]|abstract	new[212]|giv[214]|giv[215]|giv	_	_
30-29	4083-4087	that	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-30	4088-4092	will	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-31	4093-4101	continue	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-32	4102-4104	to	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-33	4105-4118	revolutionize	event[212]|abstract[214]|abstract[215]	new[212]|giv[214]|giv[215]	_	_
30-34	4119-4122	our	event[212]|abstract[214]|abstract[215]|person|abstract[218]	new[212]|giv[214]|giv[215]|giv|giv[218]	_	_
30-35	4123-4130	routine	event[212]|abstract[214]|abstract[215]|abstract[218]	new[212]|giv[214]|giv[215]|giv[218]	_	_
30-36	4131-4138	genetic	event[212]|abstract[214]|abstract[215]|abstract[218]	new[212]|giv[214]|giv[215]|giv[218]	_	_
30-37	4139-4148	diagnosis	event[212]|abstract[214]|abstract[215]|abstract[218]	new[212]|giv[214]|giv[215]|giv[218]	_	_
30-38	4149-4150	.	_	_	_	_

#Text=Recent inputs of the literature advocate closer interactions between clinicians and geneticists in the era of whole-genome sequencing .
31-1	4151-4157	Recent	abstract[219]	new[219]	_	_
31-2	4158-4164	inputs	abstract[219]	new[219]	_	_
31-3	4165-4167	of	abstract[219]	new[219]	_	_
31-4	4168-4171	the	abstract[219]|abstract[220]	new[219]|new[220]	_	_
31-5	4172-4182	literature	abstract[219]|abstract[220]	new[219]|new[220]	_	_
31-6	4183-4191	advocate	_	_	_	_
31-7	4192-4198	closer	abstract[221]	new[221]	_	_
31-8	4199-4211	interactions	abstract[221]	new[221]	_	_
31-9	4212-4219	between	abstract[221]	new[221]	_	_
31-10	4220-4230	clinicians	abstract[221]|person|person[223]	new[221]|giv|giv[223]	coref	31-10[223_0]
31-11	4231-4234	and	abstract[221]|person[223]	new[221]|giv[223]	_	_
31-12	4235-4246	geneticists	abstract[221]|person[223]|abstract	new[221]|giv[223]|new	ana	32-2
31-13	4247-4249	in	_	_	_	_
31-14	4250-4253	the	time[225]	giv[225]	_	_
31-15	4254-4257	era	time[225]	giv[225]	_	_
31-16	4258-4260	of	time[225]	giv[225]	_	_
31-17	4261-4273	whole-genome	time[225]|abstract[226]	giv[225]|new[226]	_	_
31-18	4274-4284	sequencing	time[225]|abstract[226]	giv[225]|new[226]	_	_
31-19	4285-4286	.	_	_	_	_

#Text=Among them are the identification of genetic modifiers , affecting the penetrance of homozygous pathogenic MVK : p. ( Val377Ile ) variant ; the lack of detection of pathogenic variants in patients with a clear given phenotype , such as pathogenic canonical splice site variants not covered by Sanger and panel approaches ( e.g. , ADA2 : c. -47+2T>C ) ; or large chromosomal rearrangements , encompassing several genes in patients with complex phenotypes .
32-1	4287-4292	Among	_	_	_	_
32-2	4293-4297	them	abstract	giv	coref	36-21
32-3	4298-4301	are	_	_	_	_
32-4	4302-4305	the	abstract[228]	new[228]	_	_
32-5	4306-4320	identification	abstract[228]	new[228]	_	_
32-6	4321-4323	of	abstract[228]	new[228]	_	_
32-7	4324-4331	genetic	abstract[228]|abstract[229]	new[228]|new[229]	_	_
32-8	4332-4341	modifiers	abstract[228]|abstract[229]	new[228]|new[229]	_	_
32-9	4342-4343	,	abstract[228]|abstract[229]	new[228]|new[229]	_	_
32-10	4344-4353	affecting	abstract[228]|abstract[229]	new[228]|new[229]	_	_
32-11	4354-4357	the	abstract[228]|abstract[229]|abstract[230]	new[228]|new[229]|new[230]	_	_
32-12	4358-4368	penetrance	abstract[228]|abstract[229]|abstract[230]	new[228]|new[229]|new[230]	_	_
32-13	4369-4371	of	abstract[228]|abstract[229]|abstract[230]	new[228]|new[229]|new[230]	_	_
32-14	4372-4382	homozygous	abstract[228]|abstract[229]|abstract[230]|abstract[234]	new[228]|new[229]|new[230]|new[234]	_	_
32-15	4383-4393	pathogenic	abstract[228]|abstract[229]|abstract[230]|abstract[234]	new[228]|new[229]|new[230]|new[234]	_	_
32-16	4394-4397	MVK	abstract[228]|abstract[229]|abstract[230]|abstract|abstract[234]	new[228]|new[229]|new[230]|giv|new[234]	appos	32-20
32-17	4398-4399	:	abstract[228]|abstract[229]|abstract[230]|abstract[234]	new[228]|new[229]|new[230]|new[234]	_	_
32-18	4400-4402	p.	abstract[228]|abstract[229]|abstract[230]|abstract|abstract[234]	new[228]|new[229]|new[230]|giv|new[234]	_	_
32-19	4403-4404	(	abstract[228]|abstract[229]|abstract[230]|abstract[234]	new[228]|new[229]|new[230]|new[234]	_	_
32-20	4405-4414	Val377Ile	abstract[228]|abstract[229]|abstract[230]|abstract|abstract[234]	new[228]|new[229]|new[230]|giv|new[234]	_	_
32-21	4415-4416	)	abstract[228]|abstract[229]|abstract[230]|abstract[234]	new[228]|new[229]|new[230]|new[234]	_	_
32-22	4417-4424	variant	abstract[228]|abstract[229]|abstract[230]|abstract[234]	new[228]|new[229]|new[230]|new[234]	_	_
32-23	4425-4426	;	abstract[228]	new[228]	_	_
32-24	4427-4430	the	abstract[228]|abstract[235]	new[228]|new[235]	_	_
32-25	4431-4435	lack	abstract[228]|abstract[235]	new[228]|new[235]	_	_
32-26	4436-4438	of	abstract[228]|abstract[235]	new[228]|new[235]	_	_
32-27	4439-4448	detection	abstract[228]|abstract[235]|abstract[236]	new[228]|new[235]|new[236]	_	_
32-28	4449-4451	of	abstract[228]|abstract[235]|abstract[236]	new[228]|new[235]|new[236]	_	_
32-29	4452-4462	pathogenic	abstract[228]|abstract[235]|abstract[236]|abstract[237]	new[228]|new[235]|new[236]|giv[237]	coref	32-41[242_237]
32-30	4463-4471	variants	abstract[228]|abstract[235]|abstract[236]|abstract[237]	new[228]|new[235]|new[236]|giv[237]	_	_
32-31	4472-4474	in	abstract[228]|abstract[235]|abstract[236]|abstract[237]	new[228]|new[235]|new[236]|giv[237]	_	_
32-32	4475-4483	patients	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]	new[228]|new[235]|new[236]|giv[237]|giv[238]	coref	32-71[249_238]
32-33	4484-4488	with	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]	new[228]|new[235]|new[236]|giv[237]|giv[238]	_	_
32-34	4489-4490	a	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	coref	33-17[255_239]
32-35	4491-4496	clear	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	_	_
32-36	4497-4502	given	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	_	_
32-37	4503-4512	phenotype	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	_	_
32-38	4513-4514	,	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	_	_
32-39	4515-4519	such	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	_	_
32-40	4520-4522	as	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]	_	_
32-41	4523-4533	pathogenic	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]	_	_
32-42	4534-4543	canonical	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|object[241]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|new[241]|giv[242]	_	_
32-43	4544-4550	splice	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract|object[241]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|new|new[241]|giv[242]	_	_
32-44	4551-4555	site	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|object[241]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|new[241]|giv[242]	_	_
32-45	4556-4564	variants	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]	_	_
32-46	4565-4568	not	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]	_	_
32-47	4569-4576	covered	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]	_	_
32-48	4577-4579	by	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]	_	_
32-49	4580-4586	Sanger	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]|person|abstract[245]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]|giv|new[245]	_	_
32-50	4587-4590	and	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]|abstract[245]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]|new[245]	_	_
32-51	4591-4596	panel	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]|person|abstract[245]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]|new|new[245]	_	_
32-52	4597-4607	approaches	abstract[228]|abstract[235]|abstract[236]|abstract[237]|person[238]|abstract[239]|abstract[242]|abstract[245]	new[228]|new[235]|new[236]|giv[237]|giv[238]|new[239]|giv[242]|new[245]	_	_
32-53	4608-4609	(	abstract[228]	new[228]	_	_
32-54	4610-4614	e.g.	abstract[228]	new[228]	_	_
32-55	4615-4616	,	abstract[228]	new[228]	_	_
32-56	4617-4621	ADA2	abstract[228]	new[228]	_	_
32-57	4622-4623	:	abstract[228]	new[228]	_	_
32-58	4624-4626	c.	abstract[228]|abstract	new[228]|new	_	_
32-59	4627-4635	-47+2T>C	abstract[228]	new[228]	_	_
32-60	4636-4637	)	abstract[228]	new[228]	_	_
32-61	4638-4639	;	abstract[228]	new[228]	_	_
32-62	4640-4642	or	abstract[228]	new[228]	_	_
32-63	4643-4648	large	abstract[228]|abstract[247]	new[228]|new[247]	_	_
32-64	4649-4660	chromosomal	abstract[228]|abstract[247]	new[228]|new[247]	_	_
32-65	4661-4675	rearrangements	abstract[228]|abstract[247]	new[228]|new[247]	_	_
32-66	4676-4677	,	abstract[228]|abstract[247]	new[228]|new[247]	_	_
32-67	4678-4690	encompassing	abstract[228]|abstract[247]	new[228]|new[247]	_	_
32-68	4691-4698	several	abstract[228]|abstract[247]|abstract[248]	new[228]|new[247]|giv[248]	_	_
32-69	4699-4704	genes	abstract[228]|abstract[247]|abstract[248]	new[228]|new[247]|giv[248]	_	_
32-70	4705-4707	in	abstract[228]|abstract[247]|abstract[248]	new[228]|new[247]|giv[248]	_	_
32-71	4708-4716	patients	abstract[228]|abstract[247]|abstract[248]|person[249]	new[228]|new[247]|giv[248]|giv[249]	_	_
32-72	4717-4721	with	abstract[228]|abstract[247]|abstract[248]|person[249]	new[228]|new[247]|giv[248]|giv[249]	_	_
32-73	4722-4729	complex	abstract[228]|abstract[247]|abstract[248]|person[249]|abstract[250]	new[228]|new[247]|giv[248]|giv[249]|new[250]	_	_
32-74	4730-4740	phenotypes	abstract[228]|abstract[247]|abstract[248]|person[249]|abstract[250]	new[228]|new[247]|giv[248]|giv[249]|new[250]	_	_
32-75	4741-4742	.	_	_	_	_

#Text=In those circumstances , an MSM could help find the best appropriate strategy in accordance with the patient ’s phenotype .
33-1	4743-4745	In	_	_	_	_
33-2	4746-4751	those	abstract[251]	new[251]	_	_
33-3	4752-4765	circumstances	abstract[251]	new[251]	_	_
33-4	4766-4767	,	_	_	_	_
33-5	4768-4770	an	organization[252]	giv[252]	_	_
33-6	4771-4774	MSM	organization[252]	giv[252]	_	_
33-7	4775-4780	could	_	_	_	_
33-8	4781-4785	help	_	_	_	_
33-9	4786-4790	find	_	_	_	_
33-10	4791-4794	the	abstract[253]	giv[253]	_	_
33-11	4795-4799	best	abstract[253]	giv[253]	_	_
33-12	4800-4811	appropriate	abstract[253]	giv[253]	_	_
33-13	4812-4820	strategy	abstract[253]	giv[253]	_	_
33-14	4821-4823	in	abstract[253]	giv[253]	_	_
33-15	4824-4834	accordance	abstract[253]	giv[253]	_	_
33-16	4835-4839	with	abstract[253]	giv[253]	_	_
33-17	4840-4843	the	abstract[253]|abstract[255]	giv[253]|giv[255]	coref	37-10[275_255]
33-18	4844-4851	patient	abstract[253]|person[254]|abstract[255]	giv[253]|new[254]|giv[255]	_	_
33-19	4852-4854	’s	abstract[253]|person[254]|abstract[255]	giv[253]|new[254]|giv[255]	_	_
33-20	4855-4864	phenotype	abstract[253]|abstract[255]	giv[253]|giv[255]	_	_
33-21	4865-4866	.	_	_	_	_

#Text=The role of the reference centers is to determine whether or not the clinical/anamnesis/genealogical tree is compatible with a known AID .
34-1	4867-4870	The	abstract[256]	new[256]	coref	35-11[263_256]
34-2	4871-4875	role	abstract[256]	new[256]	_	_
34-3	4876-4878	of	abstract[256]	new[256]	_	_
34-4	4879-4882	the	abstract[256]|place[258]	new[256]|giv[258]	_	_
34-5	4883-4892	reference	abstract[256]|person|place[258]	new[256]|giv|giv[258]	coref	36-10
34-6	4893-4900	centers	abstract[256]|place[258]	new[256]|giv[258]	_	_
34-7	4901-4903	is	_	_	_	_
34-8	4904-4906	to	_	_	_	_
34-9	4907-4916	determine	_	_	_	_
34-10	4917-4924	whether	_	_	_	_
34-11	4925-4927	or	_	_	_	_
34-12	4928-4931	not	_	_	_	_
34-13	4932-4935	the	abstract[259]	new[259]	_	_
34-14	4936-4967	clinical/anamnesis/genealogical	abstract[259]	new[259]	_	_
34-15	4968-4972	tree	abstract[259]	new[259]	_	_
34-16	4973-4975	is	_	_	_	_
34-17	4976-4986	compatible	_	_	_	_
34-18	4987-4991	with	_	_	_	_
34-19	4992-4993	a	abstract[260]	giv[260]	_	_
34-20	4994-4999	known	abstract[260]	giv[260]	_	_
34-21	5000-5003	AID	abstract[260]	giv[260]	_	_
34-22	5004-5005	.	_	_	_	_

#Text=If compatibility does not seem to be the case , the role is to evaluate the potential added value to perform the NGS .
35-1	5006-5008	If	_	_	_	_
35-2	5009-5022	compatibility	abstract	new	_	_
35-3	5023-5027	does	_	_	_	_
35-4	5028-5031	not	_	_	_	_
35-5	5032-5036	seem	_	_	_	_
35-6	5037-5039	to	_	_	_	_
35-7	5040-5042	be	_	_	_	_
35-8	5043-5046	the	abstract[262]	new[262]	_	_
35-9	5047-5051	case	abstract[262]	new[262]	_	_
35-10	5052-5053	,	_	_	_	_
35-11	5054-5057	the	abstract[263]	giv[263]	_	_
35-12	5058-5062	role	abstract[263]	giv[263]	_	_
35-13	5063-5065	is	_	_	_	_
35-14	5066-5068	to	_	_	_	_
35-15	5069-5077	evaluate	_	_	_	_
35-16	5078-5081	the	abstract[264]	new[264]	coref	36-2[266_264]
35-17	5082-5091	potential	abstract[264]	new[264]	_	_
35-18	5092-5097	added	abstract[264]	new[264]	_	_
35-19	5098-5103	value	abstract[264]	new[264]	_	_
35-20	5104-5106	to	abstract[264]	new[264]	_	_
35-21	5107-5114	perform	abstract[264]	new[264]	_	_
35-22	5115-5118	the	abstract[264]|abstract[265]	new[264]|giv[265]	coref	36-14[269_265]
35-23	5119-5122	NGS	abstract[264]|abstract[265]	new[264]|giv[265]	_	_
35-24	5123-5124	.	_	_	_	_

#Text=If this value appears to be low , the reference center recommends that no NGS be conducted in discussion with geneticists .
36-1	5125-5127	If	_	_	_	_
36-2	5128-5132	this	abstract[266]	giv[266]	_	_
36-3	5133-5138	value	abstract[266]	giv[266]	_	_
36-4	5139-5146	appears	_	_	_	_
36-5	5147-5149	to	_	_	_	_
36-6	5150-5152	be	_	_	_	_
36-7	5153-5156	low	_	_	_	_
36-8	5157-5158	,	_	_	_	_
36-9	5159-5162	the	organization[268]	giv[268]	_	_
36-10	5163-5172	reference	person|organization[268]	giv|giv[268]	_	_
36-11	5173-5179	center	organization[268]	giv[268]	_	_
36-12	5180-5190	recommends	_	_	_	_
36-13	5191-5195	that	_	_	_	_
36-14	5196-5198	no	abstract[269]	giv[269]	_	_
36-15	5199-5202	NGS	abstract[269]	giv[269]	_	_
36-16	5203-5205	be	_	_	_	_
36-17	5206-5215	conducted	_	_	_	_
36-18	5216-5218	in	_	_	_	_
36-19	5219-5229	discussion	abstract[270]	new[270]	coref	37-3[272_270]
36-20	5230-5234	with	abstract[270]	new[270]	_	_
36-21	5235-5246	geneticists	abstract[270]|abstract	new[270]|giv	_	_
36-22	5247-5248	.	_	_	_	_

#Text=Thus , this discussion decreases the number of individuals whose phenotype is not typically enough .
37-1	5249-5253	Thus	_	_	_	_
37-2	5254-5255	,	_	_	_	_
37-3	5256-5260	this	abstract[272]	giv[272]	_	_
37-4	5261-5271	discussion	abstract[272]	giv[272]	_	_
37-5	5272-5281	decreases	_	_	_	_
37-6	5282-5285	the	abstract[273]	new[273]	_	_
37-7	5286-5292	number	abstract[273]	new[273]	_	_
37-8	5293-5295	of	abstract[273]	new[273]	_	_
37-9	5296-5307	individuals	abstract[273]|person[274]	new[273]|new[274]	_	_
37-10	5308-5313	whose	abstract[273]|person[274]|abstract[275]	new[273]|new[274]|giv[275]	_	_
37-11	5314-5323	phenotype	abstract[273]|person[274]|abstract[275]	new[273]|new[274]|giv[275]	_	_
37-12	5324-5326	is	abstract[273]|person[274]	new[273]|new[274]	_	_
37-13	5327-5330	not	abstract[273]|person[274]	new[273]|new[274]	_	_
37-14	5331-5340	typically	abstract[273]|person[274]	new[273]|new[274]	_	_
37-15	5341-5347	enough	abstract[273]|person[274]	new[273]|new[274]	_	_
37-16	5348-5349	.	_	_	_	_
